1. Home
  2. THRM vs DSGN Comparison

THRM vs DSGN Comparison

Compare THRM & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gentherm Inc

THRM

Gentherm Inc

HOLD

Current Price

$30.23

Market Cap

844.7M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$13.33

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THRM
DSGN
Founded
1991
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
844.7M
819.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
THRM
DSGN
Price
$30.23
$13.33
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$37.20
$15.25
AVG Volume (30 Days)
228.0K
469.9K
Earning Date
04-23-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$554,979,000.00
N/A
Revenue This Year
$4.96
N/A
Revenue Next Year
$7.12
N/A
P/E Ratio
$215.00
N/A
Revenue Growth
50.16
N/A
52 Week Low
$25.47
$3.11
52 Week High
$39.48
$17.25

Technical Indicators

Market Signals
Indicator
THRM
DSGN
Relative Strength Index (RSI) 56.68 55.22
Support Level $27.38 $9.71
Resistance Level $32.25 $13.54
Average True Range (ATR) 1.10 1.07
MACD 0.17 0.02
Stochastic Oscillator 51.11 25.42

Price Performance

Historical Comparison
THRM
DSGN

About THRM Gentherm Inc

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the USA, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: